Tokyo Tape
Sign in
← ASKA Pharmaceutical Holdings

Quarterly report · Q3

4886.TEDINET S100Q4CE
Period2022-04-01 → 2022-12-31
Filed2023-02-09
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥47.3bn2022-04-01 → 2022-12-31Cons.Net sales
Revenue¥56.6bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥44.2bn2021-04-01 → 2021-12-31Cons.Net sales
Operating income¥5.0bn2022-04-01 → 2022-12-31Cons.Operating income
Operating income¥4.7bn2021-04-01 → 2021-12-31Cons.Operating income
Ordinary income¥5.2bn2022-04-01 → 2022-12-31Cons.Ordinary income
Ordinary income¥4.9bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥4.8bn2021-04-01 → 2021-12-31Cons.Ordinary income
Profit before tax¥5.4bn2022-04-01 → 2022-12-31Cons.Income before income taxes
Profit before tax¥5.8bn2021-04-01 → 2021-12-31Cons.Income before income taxes
Net income (owners)¥4.2bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.3bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥4.1bn2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent
Net income¥4.2bn2022-04-01 → 2022-12-31Cons.Profit loss
Net income¥4.1bn2021-04-01 → 2021-12-31Cons.Profit loss
Total assets¥90.8bnat 2022-12-31Cons.Assets
Total assets¥83.3bnat 2022-03-31Cons.Assets
Total assets¥87.5bnat 2021-12-31Cons.Total assets (5-year summary)
Total liabilities¥36.7bnat 2022-12-31Cons.Liabilities
Total liabilities¥34.4bnat 2022-03-31Cons.Liabilities
Net assets / equity¥54.1bnat 2022-12-31Cons.Net assets
Net assets / equity¥48.9bnat 2022-03-31Cons.Net assets
Net assets / equity¥48.4bnat 2021-12-31Cons.Net assets (5-year summary)
Cash and deposits¥18.5bnat 2022-12-31Cons.Cash and deposits
Cash and deposits¥12.1bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥148.192022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥64.972022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥151.222021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥143.762021-04-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥242.12021-10-01 → 2021-12-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio59.6%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio58.7%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio55.3%at 2021-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 34
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-12-31¥196m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-12-31¥155m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-12-31¥41m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-12-31−¥26m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥41m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥41m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥767m
jpcrp040300-q3r_E35791-000Animal Health Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥5.2bn
jpcrp040300-q3r_E35791-000Animal Health Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥5.2bn
jpcrp040300-q3r_E35791-000Animal Health Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥417m
jpcrp040300-q3r_E35791-000Pharmaceutical Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥41.9bn
jpcrp040300-q3r_E35791-000Pharmaceutical Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥41.9bn
jpcrp040300-q3r_E35791-000Pharmaceutical Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥5.4bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-12-31¥47.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-12-31¥47.3bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-12-31¥41m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-12-31¥5.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2021-04-01 → 2021-12-31¥158m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2021-04-01 → 2021-12-31¥116m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2021-04-01 → 2021-12-31¥41m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2021-04-01 → 2021-12-31−¥42m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-12-31−¥41m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-12-31−¥41m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-12-31−¥495m
jpcrp040300-q3r_E35791-000Animal Health Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥4.4bn
jpcrp040300-q3r_E35791-000Animal Health Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥4.4bn
jpcrp040300-q3r_E35791-000Animal Health Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥329m
jpcrp040300-q3r_E35791-000Pharmaceutical Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥39.7bn
jpcrp040300-q3r_E35791-000Pharmaceutical Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥39.7bn
jpcrp040300-q3r_E35791-000Pharmaceutical Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥4.9bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-12-31¥44.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-12-31¥44.2bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-12-31¥41m
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-12-31¥5.2bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 340
ItemContextValueUnit
Other noiCurrentYTDDuration70000000JPY
Non operating incomePrior1YTDDuration367000000JPY
Non operating incomeCurrentYTDDuration402000000JPY
Interest expenses noePrior1YTDDuration43000000JPY
Interest expenses noeCurrentYTDDuration38000000JPY
Expenses of inactive non current assets noePrior1YTDDuration137000000JPY
Expenses of inactive non current assets noeCurrentYTDDuration40000000JPY
Other noePrior1YTDDuration72000000JPY
Other noeCurrentYTDDuration118000000JPY
Non operating expensesPrior1YTDDuration254000000JPY
Non operating expensesCurrentYTDDuration197000000JPY
Ordinary incomePrior1YTDDuration4790000000JPY
Ordinary incomeCurrentYTDDuration5246000000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration9425000000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration－JPY
Gain on sales of investment securities eiPrior1YTDDuration－JPY
Gain on sales of investment securities eiCurrentYTDDuration121000000JPY
Extraordinary incomePrior1YTDDuration9425000000JPY
Extraordinary incomeCurrentYTDDuration121000000JPY
Impairment loss elPrior1YTDDuration5921000000JPY
Impairment loss elCurrentYTDDuration－JPY
Other elPrior1YTDDuration2444000000JPY
Other elCurrentYTDDuration－JPY
Extraordinary lossPrior1YTDDuration8366000000JPY
Extraordinary lossCurrentYTDDuration－JPY
Income before income taxesPrior1YTDDuration5849000000JPY
Income before income taxesCurrentYTDDuration5367000000JPY
Income taxes currentPrior1YTDDuration1048000000JPY
Income taxes currentCurrentYTDDuration1036000000JPY
Income taxes deferredPrior1YTDDuration717000000JPY
Income taxes deferredCurrentYTDDuration148000000JPY
Income taxesPrior1YTDDuration1766000000JPY
Income taxesCurrentYTDDuration1184000000JPY
Profit lossPrior1YTDDuration4082000000JPY
Profit lossCurrentYTDDuration4183000000JPY
Profit loss attributable to owners of parentPrior1YTDDuration4082000000JPY
Profit loss attributable to owners of parentCurrentYTDDuration4183000000JPY
Profit lossPrior1YTDDuration4082000000JPY
Profit lossCurrentYTDDuration4183000000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration61000000JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration858000000JPY
Remeasurements of defined benefit plans net of tax ociPrior1YTDDuration22000000JPY
Remeasurements of defined benefit plans net of tax ociCurrentYTDDuration20000000JPY
Share of other comprehensive income of associates accounted for using equity method ociPrior1YTDDuration89000000JPY
Share of other comprehensive income of associates accounted for using equity method ociCurrentYTDDuration477000000JPY
Other comprehensive incomePrior1YTDDuration173000000JPY
Other comprehensive incomeCurrentYTDDuration1355000000JPY
Comprehensive incomePrior1YTDDuration4256000000JPY
Comprehensive incomeCurrentYTDDuration5538000000JPY
Comprehensive income attributable to owners of the parentPrior1YTDDuration4256000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-04-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass